Kinetics and predictive value of HBcrAg , HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV ‐infected patients
Journal of Viral Hepatitis · 2023-04 · 30 (4) · 283-286
DOI: 10.1111/jvh.13804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 23.01.2023. Verfasst von Lisa Sandmann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis D, Chronic, Hepatitis D. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujirebio Europe, Roche.
Abstract (Originalsprache)
The entry inhibitor bulevirtide (BLV) is a new treatment option for patients with chronic hepatitis D virus (HDV) infection and compensated liver disease. The aim of this study was to investigate the kinetic and predictive value of markers reflecting HBV cccDNA transcriptional activity and host immune response activity during BLV treatment in a real‐life cohort of HDV infected patients. Levels of HDV RNA, HBV RNA, hepatitis B core related antigen (HBcrAg) and hepatitis B core antibodies (anti‐HBc) were measured in 16 patients before (BL), after three (3M) and six (6M) months of treatment with BLV. All patients received nucleos(t)ide analogue treatment. HDV RNA declined in all patients during treatment. 38% (6/16) showed ≥ 2 log HDV RNA decline from BL to 6M and 11 patients (69%) normalized ALT levels. HBV RNA levels were low and only detectable in two to four patients. HBcrAg levels declined in 75% (12/16) of patients. Median HBcrAg levels declined significantly from BL to 6M (3.75 logU/ml (IQR 2.93‐4.78) vs. 3.4 logU/ml (IQR 2‐4.68), p=0.002). A similar trend was shown for anti‐HBc between BL and 6M. Levels of HBcrAg or anti‐HBc did not differ significantly between patients with or without ≥ 2 log HDV RNA decline from BL to 6M.After 6 months treatment with BLV, levels of HBcrAg showed a significant decline, while HBV RNA and anti‐HBc levels did not change. Reduction of HBV cccDNA transcriptional activity and immunological effects of antiviral treatment might explain these changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
- Excellence Cluster RESIST, Excellence Initiative Hannover Medical School, Hannover, Germany.
- German Center for Infection Research (DZIF), Hannover, Braunschweig, Germany.
- Center for Individualised Infection Medicine, Helmholtz Center for Infection Research, Braunschweig, Germany.
ORCID-Profile: Lisa Sandmann, Markus Cornberg
Förderung
- Fujirebio Europe
- Roche
Zitieren
APA
Sandmann, L., Deterding, K., Bremer, B., Port, K., Cornberg, M., Wedemeyer, H., & Maasoumy, B. (2023). Kinetics and predictive value of HBcrAg , HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV ‐infected patients. Journal of Viral Hepatitis, 30(4), 283-286. https://doi.org/10.1111/jvh.13804
Vancouver
Sandmann L, Deterding K, Bremer B, Port K, Cornberg M, Wedemeyer H, et al. Kinetics and predictive value of HBcrAg , HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV ‐infected patients. Journal of Viral Hepatitis. 2023;30(4):283-286. doi:10.1111/jvh.13804
BibTeX
@article{Sandmann2023,
author = {Sandmann, Lisa and Deterding, Katja and Bremer, Birgit and Port, Kerstin and Cornberg, Markus and Wedemeyer, Heiner and Maasoumy, Benjamin},
title = {Kinetics and predictive value of HBcrAg , HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV ‐infected patients},
journal = {Journal of Viral Hepatitis},
year = {2023},
volume = {30},
number = {4},
pages = {283--286},
doi = {10.1111/jvh.13804}
}
EUVIMED